Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis and 14.0 percent on an organic2 basis, all compared to the prior year period.…
Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended March 31, 2023 net earnings were $1.4 billion, or $1.94 per diluted common share and non-GAAP adjusted…
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2023. Key financial data First quarter highlights Note: Financial information for the three months ended March 31, 2022 throughout this press release has been revised…
If you have depression, you’ve probably experienced feeling so sluggish that even tiny tasks like washing your face seem insurmountable. This feeling — commonly known as “depression fatigue” — is more than mere tiredness. “It is not the same feeling you…
Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that it has signed a distribution and collaboration agreement with Adalvo for exclusive Sandoz rights to commercialize six products in the US across key therapeutic areas, including antifungal/antibiotic, oncology…
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Cosentyx® (secukinumab) in adults with active moderate to severe hidradenitis suppurativa…
Novartis will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, including advancements in breast cancer, prostate cancer and lung cancer from more than 40 Novartis-sponsored and investigator-led trials. Primary results…
Novartis today announced detailed results from the Phase III APPOINT-PNH trial of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with paroxysmal nocturnal hemoglobinuria (PNH)1. The trial met its primary endpoint and demonstrated clinically meaningful benefits across secondary…
Ad hoc announcement pursuant to Art. 53 LR Basel, April 25, 2023 – commenting on the quarter, Vas Narasimhan MD, CEO of Novartis, said: “Novartis delivered strong growth to start 2023, driven by our in-market growth brands, in particular Entresto, Kisqali and Kesimpta. The Pluvicto and Scemblix launches continue…
Annonce événementielle au sens de l’art. 53 RC Bâle, le 25 avril 2023 – Commentant les résultats du T1, Dr Vas Narasimhan CEO de Novartis, a déclaré: «Novartis a commencé l’exercice 2023 en réalisant une forte croissance. Celle-ci a été assurée par nos…
Ad-hoc-Mitteilung gemäss Art. 53 KR Basel, 25. April 2023 – Die Ergebnisse des ersten Quartals kommentierte Vas Narasimhan, CEO von Novartis: «Novartis ist mit einem kräftigen Wachstum in das Jahr 2023 gestartet, angetrieben durch unsere Wachstumsmarken im Markt, insbesondere Entresto, Kisqali und Kesimpta. Die Einführung von Pluvicto und Scemblix verläuft…
Novartis today announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® (ofatumumab) had fewer disability worsening events and low brain volume change versus those who started on…